Cover Image
市場調查報告書

Stratatech Corporation的產品平台分析

Stratatech Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321953
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Stratatech Corporation的產品平台分析 Stratatech Corporation - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 25 Pages
簡介

Stratatech Corporation是總公司設立於美國的再生醫療品開發企業,提供藉由患者本身皮膚來促進傷口癒合的stratagraft,以及具有抗菌功能促進自然癒合的expressgraft等傷口敷料產品。

本報告提供Stratatech Corporation 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Stratatech Corporation 基本資料

  • Stratatech Corporation 概要
  • 主要資訊
  • 企業資料

Stratatech Corporation :R&D概要

  • 主要的治療範圍

Stratatech Corporation :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Stratatech Corporation :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 後期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Stratatech Corporation :藥物簡介

  • StrataGraft Skin Tissue
  • Cathelicidin
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers
  • Interleukin-12

Stratatech Corporation :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Stratatech Corporation :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07330CDB

Summary

Global Markets Direct's, 'Stratatech Corporation - Product Pipeline Review - 2015', provides an overview of the Stratatech Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Stratatech Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Stratatech Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Stratatech Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Stratatech Corporation's pipeline products

Reasons to buy

  • Evaluate Stratatech Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Stratatech Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Stratatech Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Stratatech Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Stratatech Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Stratatech Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Stratatech Corporation Snapshot
    • Stratatech Corporation Overview
    • Key Information
    • Key Facts
  • Stratatech Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Stratatech Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Stratatech Corporation - Pipeline Products Glance
    • Stratatech Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Stratatech Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Stratatech Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Stratatech Corporation - Drug Profiles
    • StrataGraft Skin Tissue
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cathelicidin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Interleukin-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Stratatech Corporation - Pipeline Analysis
  • Stratatech Corporation - Pipeline Products by Target
  • Stratatech Corporation - Pipeline Products by Molecule Type
  • Stratatech Corporation - Pipeline Products by Mechanism of Action
  • Stratatech Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Stratatech Corporation, Key Information
  • Stratatech Corporation, Key Facts
  • Stratatech Corporation - Pipeline by Indication, 2015
  • Stratatech Corporation - Pipeline by Stage of Development, 2015
  • Stratatech Corporation - Monotherapy Products in Pipeline, 2015
  • Stratatech Corporation - Phase III, 2015
  • Stratatech Corporation - Phase I, 2015
  • Stratatech Corporation - Preclinical, 2015
  • Stratatech Corporation - Discovery, 2015
  • Stratatech Corporation - Pipeline by Target, 2015
  • Stratatech Corporation - Pipeline by Molecule Type, 2015
  • Stratatech Corporation - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Stratatech Corporation - Pipeline by Top 10 Indication, 2015
  • Stratatech Corporation - Pipeline by Stage of Development, 2015
  • Stratatech Corporation - Monotherapy Products in Pipeline, 2015
  • Stratatech Corporation - Pipeline by Top 10 Target, 2015
  • Stratatech Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Stratatech Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top